La cadena de opciones muestra datos clave de las opciones de acciones de Cognition Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Cognition Therapeutics..

Cognition Therapeutics (NASDAQ:CGTX) Bolsa, Cadena de Opciones

COGNITION THERAPEUTICS INC

Cognition Therapeutics

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics Inc

News

Press Releases

Power Metallic Mines (TSXV: PNPN | OTCQB: PNPNF) Issues Summer 2025 "BIG Picture" Exploration Update – More Stocks Inside

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

Health Care

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

Earnings

Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

Financing

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target

AIRI

BTCM

CGTX

PNPNF

SAFX

SNYR

STKH

TSXV:PNPN

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Context Therapeutics

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics

Cybin

Journey Medical Corporation - Common Stock

Journey Medical

ImageneBio

MediWound

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies Hldgs

Nutriband

Organigram Global

Omeros

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Cassava Sciences

Scilex Holding

Sol-Gel Technologies Ltd. - Ordinary Shares

Sol-Gel Technologies

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Ventyx Biosciences

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

Chardan Capital

HC Wainwright & Co.

B. Riley Securities

Rodman & Renshaw

Oppenheimer

Screenshot 2025-07-24 at 1.57.48 PM

Biotech

Cognition Therapeutics&#39; End-Of-Phase 2 Trial Meeting With FDA Could Kick Off Phase 3 Trial For Its Alzheimer&#39;s Candidate Zervimesine

Screenshot 2025-06-11 at 5.27.02 PM

Armed With Donation From Trial Participant&#39;s Family, Cognition (Nasdaq: CGTX) Initiates Expanded Access Program For Experimental DLB Drug

Screenshot 2025-05-22 at 5.40.49 PM

General

Cognition Therapeutics Phase 2 Trials Of Zervimesine Show Promise In Treating Dry AMD, Alzheimer&#39;s Disease And Dementia With Lewy Bodies

Screenshot 2025-04-08 at 6.45.45 PM

2025 Is Shaping Up To Be A Big Year For This Drug Maker Working To Cure Dementia

Screenshot 2025-02-05 at 6.32.21 PM

Cognition Therapeutics Presents Phase 2 Results For Drug To Fight DLB At International Conference

Screenshot 2025-01-10 at 6.53.28 PM

Cognition Therapeutics Is Targeting A Critical Form Of Dementia

Screenshot 2024-12-19 at 6.36.01 PM

Topline Results Are In: Cognition Therapeutics&#39; Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial

Screenshot 2024-12-11 at 6.36.45 PM

Cognition Therapeutics Hopes To Affirm CT1812 Holds The Key To Slowing Progression Of Dementia With Lewy Bodies

Comments

Cognition Therapeutics

Cognition Therapeutics (CGTX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL